Monoclonal antibodies have evolved from research tools to powerful therapeutics in the past
30 years. Clinical success rates of antibodies have exceeded expectations, resulting in …

Antibody conjugates are a diverse class of therapeutics consisting of a cytotoxic agent linked
covalently to an antibody or antibody fragment directed toward a specific cell surface target …

Highlights•Antibody–drug conjugates represent an exciting new class of cancer
therapeutics.•ADCs comprise monoclonal antibodies that selectively deliver potent cytotoxic …

Introduction In the field of bioconjugates, the focus on antibody–drug conjugates (ADCs)
with novel payloads beyond the traditional categories of potent cytotoxic agents is …

Introduction: Antibody drug conjugates now make up a significant fraction of biopharma's
oncology pipeline due to great advances in the understanding of the three key components …

Conventional anticancer therapeutics often suffer from lack of specificity, resulting in poor
therapeutic indexes and substantial toxicities to normal healthy tissues. Monoclonal …

Antibody-drug conjugates (ADCs) are innovative biopharmaceutical products in which a
monoclonal antibody is linked to a small molecule drug with a stable linker. Most of the …

The requirements for a cell surface molecule to be suitable as an antibody-drug conjugate
target are stringent. The notion that antibodies-directed toward targets on the surface of …

Antibody–drug conjugates (ADCs) are one of the fastest growing classes of oncology
therapeutics. After half a century of research, the approvals of brentuximab vedotin (in 2011) …

Immunoconjugates are specific, highly effective, minimally toxic anticancer therapies that are
beginning to show promise in the clinic. Immunoconjugates consist of three separate …